Three doses of a Covid vaccine may not be able to curb the rapid spread of the highly transmissible Omicron variant of Covid, warned Ugur Sahin, CEO of Germany-based BioNTech, which is developing a vaccine to curb Omicron variant now
PM Narendra Modi reviewed the development of COVID-19 vaccine candidate ZyCOV-D in Ahmedabad.
As panic strikes with the news of a new variant of COVID-19, which was detected in the UK, there s some good news coming from pharma giant BioNTech. The German pharmaceutical company is confident that its vaccine for coronavirus will work effectively against the new variant of COVID strain reported in Britain.
BioNTech is basing its confidence on the fact that the proteins on the UK variant are 99 percent similar on the prevailing strains, which is why the vaccine will be effective. Scientifically, it is highly likely that the immune response by this vaccine also can deal with the new virus variant. We don t know at the moment if our vaccine is also able to provide protection against this new variant, said Ugur Sahin, the co-founder of BioNTech, expressing a hint of caution.